Relief Therapeutics and NeuroRx Inc., have reportedly announced the official completion of their partnership agreement for the commercialization of RLF-100 at the global level. The two companies have reportedly agreed for sharing all proceeds generated from the sales of RLF-100 for all indications associated with COVID-19 and plausibly other respiratory indications on a worldwide basis.
Sources state that both the players have also consented that NeuroRx will steer the commercialization campaign in Canada, Israel, and the United States, while Relief will steer the commercialization campaign in Europe and the rest of the world. The companies have reportedly decided on the allocation of profits to NeuroRx and Relief on a 50/50 basis in Canada, Israel, and the U.S., with 85/15 (favoring Relief) in Europe, and 80/20 in the remaining territories.
According to Raghuram Selvaraju, the Chairman of the Board of Relief, the company is thrilled to reach this deal with NeuroRx and believes in its capability as a partner for rapid clinical development and expedient and timely interaction with regulatory authorities. He has further stated that the company eagerly looks ahead to productively and collaboratively working together for the maximization of the total franchise value for its shareholders, while getting this potentially life-saving drug to patients at the fastest rate possible.
As per sources, the two organizations have effectively taken steps towards increasing the manufacturing of the drug aviptadil and are currently in the last stages of contracting with a finish manufacturer and a nationwide distribution partner. Both the companies are expected to have distribution, manufacturing, and logistics capacity in place by January 2021 for the production of sufficient drug quantities for the effective treatment of almost 150,000 patients with RLF-100 each month.
Jonathan Javitt, NeuroRx’s Chief Executive Officer, has stated that as the global pandemic has been consistently devastating communities and families, the company’s small team is encouraged by the early promise that has been witnessed in Sami Said’s scientific legacy. The company is working round the clock for bringing this drug to patients, added Javitt.